Expression and prognostic role of IKBKE and TBK1 in stage I non-small cell lung cancer

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. doi:10.3322/caac.2116623335087
   PubMed Web of Science ®Google Scholar
• D’Addario G, Felip E; Group EGW. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:68–70. doi:10.1093/annonc/mdp13219454467
   PubMed Web of Science ®Google Scholar
• Santarpia M, Altavilla G, Pitini V, Rosell R. Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors. Future Oncol. 2015;11:1259–1274. doi:10.2217/fon.14.32025832881
   PubMed Web of Science ®Google Scholar
• Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification. Chest. 2011;140:1494–1502. doi:10.1378/chest.10-327921622548
   PubMed Web of Science ®Google Scholar
• Custodio AB, Gonzalez-Larriba JL, Bobokova J, et al. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. J Thorac Oncol. 2009;4:891–910. doi:10.1097/JTO.0b013e3181a4b8fb19433989
   PubMed Web of Science ®Google Scholar
• Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–2597. doi:10.1056/NEJMoa04362315972865
   PubMed Web of Science ®Google Scholar
• Verhelst K, Verstrepen L, Carpentier I, et al. IkappaB kinase epsilon (IKKepsilon): a therapeutic target in inflammation and cancer. Biochem Pharmacol. 2013;85:873–880. doi:10.1016/j.bcp.2013.01.00723333767
   PubMed Web of Science ®Google Scholar
• Chien Y, Kim S, Bumeister R, et al. RalB GTPase-mediated activation of the IκB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell. 2006;127(1):0–170. doi:10.1016/j.cell.2006.08.034
   Web of Science ®Google Scholar
• Shimada T, Kawai T, Takeda K, et al. IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases. Int Immunol. 1999;11:1357–1362. doi:10.1093/intimm/11.8.135710421793
   PubMed Web of Science ®Google Scholar
• Larabi A, Dev JM, Ng SL, et al. Crystal structure and mechanism of activation of TANK-binding kinase 1. Cell Rep. 2013;3:734–746. doi:10.1016/j.celrep.2013.01.03423453971
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 2007;13(11):460–469. doi:10.1016/j.molmed.2007.09.00218029230
   PubMed Web of Science ®Google Scholar
• Chau TL, Gioia R, Gatot J-S, et al. Are the IKKs and IKK-related kinases TBK1 and IKK-? similarly activated? Trends Biochem Sci. 2008;33(4):171–180. doi:10.1016/j.tibs.2008.01.00218353649
   PubMed Web of Science ®Google Scholar
• Pomerantz JL, Baltimore D. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. Embo J. 1999;18(23):6694–6704. doi:10.1093/emboj/18.23.669410581243
   PubMed Web of Science ®Google Scholar
• Nomura F, Kawai T, Nakanishi K, Akira S. NF-kappaB activation through IKK-i-dependent I-TRAF/TANK phosphorylation. Genes Cells. 2000;5(3):191–202.10759890
   PubMed Web of Science ®Google Scholar
• Gatot JS, Gioia R, Chau TL, et al. Lipopolysaccharide-mediated interferon regulatory factor activation involves TBK1-IKKϵ-dependent Lys63-linked polyubiquitination and phosphorylation of TANK/I-TRAF. J Biol Chem. 2007;282(43):31131. doi:10.1074/jbc.M70169020017823124
   PubMed Web of Science ®Google Scholar
• Fujita F, Taniguchi Y, Kato T, et al. Identification of NAP1, a regulatory subunit of IκB kinase-related kinases that potentiates NF-κB signaling. Mol Cell Biol. 2003;23(21):7780–7793. doi:10.1128/mcb.23.21.7780-7793.200314560022
   PubMed Web of Science ®Google Scholar
• Ryzhakov G, Randow F. SINTBAD, a novel component of innate antiviral immunity, shares a TBK1-binding domain with NAP1 and TANK. Embo J. 2007;26(13):3180–3190. doi:10.1038/sj.emboj.760174317568778
   PubMed Web of Science ®Google Scholar
• Eddy SF, Guo S, Demicco EG, et al. Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells. Cancer Res. 2005;65(24):11375. doi:10.1158/0008-5472.CAN-04-455716357145
   PubMed Web of Science ®Google Scholar
• Guan H, Zhang H, Cai J, et al. IKBKE is over-expressed in glioma and contributes to resistance of glioma cells to apoptosis via activating NF-κB. J Pathol. 2011;223(3):436–445. doi:10.1002/path.281521171089
   PubMed Web of Science ®Google Scholar
• Lee SE, Hong M, Cho J, et al. IKKε and TBK1 expression in gastric cancer. Oncotarget. 2016;8(10):16233–16242.
   Google Scholar
• Cheng A, Guo J, Henderson-Jackson E, Kim D, Malafa M, Coppola D. Iκb kinase ε expression in pancreatic ductal adenocarcinoma. Am J Clin Pathol. 2011;136(1):60–66. doi:10.1309/AJCP2JJGYNIUAS2V21685032
   PubMed Web of Science ®Google Scholar
• Guo JP, Shu SK, He L, et al. Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol. 2009;175(1):324–333. doi:10.2353/ajpath.2009.08076719497997
   PubMed Web of Science ®Google Scholar
• Ghatalia P, Yang ES, Lasseigne BN, et al. Kinase gene expression profiling of metastatic clear cell renal cell carcinoma tissue identifies potential new therapeutic targets. PLoS One. 2016;11(8):e0160924. doi:10.1371/journal.pone.016092427574806
   PubMed Web of Science ®Google Scholar
• Guo J, Kim D, Gao J, et al. IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer. Oncogene. 2013;32(2):151–159. doi:10.1038/onc.2012.3922330135
   PubMed Web of Science ®Google Scholar
• Seo SI, Song SY, Kang MR, et al. Immunohistochemical analysis of NF-kappaB signaling proteins IKKepsilon, p50/p105, p52/p100 and RelA in prostate cancers. Apmis. 2009;117:623–628. doi:10.1111/j.1600-0463.2009.02506.x19664134
   PubMed Web of Science ®Google Scholar
• Kim JY, Welsh EA, Oguz U, et al. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci USA. 2013;110:12414–12419. doi:10.1073/pnas.122067411023836654
   PubMed Web of Science ®Google Scholar
• Ma X, Helgason E, Phung QT, et al. Molecular basis of tank-binding kinase 1 activation by transautophosphorylation. Proc Natl Acad Sci USA. 2012;109:9378–9383. doi:10.1073/pnas.112155210922619329
   PubMed Web of Science ®Google Scholar
• Zhou AY, Shen RR, Kim E, et al. IKK”-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex. Cell Rep. 2013;3:724–733. doi:10.1016/j.celrep.2013.02.00423453969
   PubMed Web of Science ®Google Scholar
• Rokavec M, Luo JL. The transient and constitutive inflammatory signaling in tumorigenesis. Cell Cycle. 2012;11:2587–2588. doi:10.4161/cc.2113922751429
   PubMed Web of Science ®Google Scholar
• Gulen MF, Bulek K, Xiao H, et al. Inactivation of the enzyme GSK3α by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance. Immunity. 2012;37(5):800–812. doi:10.1016/j.immuni.2012.08.01923142783
   PubMed Web of Science ®Google Scholar
• Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960–976. doi:10.1016/j.cell.2017.02.00428283069
   PubMed Web of Science ®Google Scholar
• Yu J, Zhou X, Chang M, et al. Regulation of T-cell activation and migration by the kinase TBK1 during neuroinflammation. Nat Commun. 2015;6:6074. doi:10.1038/ncomms707425606824
   PubMed Web of Science ®Google Scholar
• Bodur C, Kazyken D, Huang K, et al. The IKK-related kinase TBK1 activates mTORC1 directly in response to growth factors and innate immune agonists. Embo J. 2018;37:19–38. doi:10.15252/embj.20169616429150432
   PubMed Web of Science ®Google Scholar
• Zhang H, Chen L, Cai SH, Cheng H. Identification of TBK1 and IKKε, the non-canonical IκB kinases, as crucial pro-survival factors in HTLV-1-transformed T lymphocytes. Leuk Res. 2016;46:37–44. doi:10.1016/j.leukres.2016.04.01227123832
   PubMed Web of Science ®Google Scholar
• Qin B, Cheng K, Gite S, Ostendorff HP, Narod S, Rothschild KJ. Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells. Breast Cancer Res. 2010;12(5):R74. doi:10.1186/bcr272220863366
   PubMed Web of Science ®Google Scholar
• Li H, Chen L, Zhang A, et al. Silencing of IKKε using siRNA inhibits proliferation and invasion of glioma cells in vitro and in vivo. Int J Oncol. 2012;41(1):169–178. doi:10.3892/ijo.2012.145222552702
   PubMed Web of Science ®Google Scholar
• Lu J, Yang Y, Guo G, et al. Ikbke regulates cell proliferation and epithelial-mesenchymal transition of human malignant glioma via the hippo pathway. Oncotarget. 2017;8(30):49502–49514. doi:10.18632/oncotarget.1773828548934
   PubMedGoogle Scholar
• Niederberger E, Möser C, Kynast K, et al. The non-canonical IjB kinafound IKBKE/TBK1-sensitive acute myeloid leukemia (AML) cells tend to have MYC ses IKKe and TBK1 as potential targets for the development of novel therapeutic drugs. Curr Mol Med. 2012;13:7.
   Google Scholar
• Zhu Z, Aref AR, Cohoon TJ, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014. doi:10.1158/2159-8290.CD-13-0646
   Web of Science ®Google Scholar
• Guo JP, Coppola D, Cheng JQ. IKBKE protein activates AKT independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J Biol Chem. 2011;286:37389–37398. doi:10.1074/jbc.M111.28743321908616
   PubMed Web of Science ®Google Scholar
• Chen J, Somanath PR, Razorenova O, et al. AKT1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med. 2005;11(11):1188–1196. doi:10.1038/nm130716227992
   PubMed Web of Science ®Google Scholar
• Li J, Huang J, Jeong JH, et al. Selective TBK1/IKKi dual inhibitors with anticancer potency. Int J Cancer. 2014;134(8):1972–1980. doi:10.1002/ijc.2850724150799
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang Z, Huang K, et al. PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma. Cancer Lett. 2019;443:91–107. doi:10.1016/j.canlet.2018.11.03430529153
   PubMed Web of Science ®Google Scholar
• Zhang Y, Unnithan RVM, Hamidi A, et al. TANK-binding kinase 1 is a mediator of platelet-induced EMT in mammary carcinoma cell. Faseb J. 2019;fj201801936RRR. doi:10.1096/fj.201801936RRR
   Web of Science ®Google Scholar